Peter MacCallum Cancer Centre signs agreement with ASX-listed Prescient Therapeutics
Prescient Therapeutics has inked a new deal with leading research organisation Peter MacCallum Cancer Centre...
Prescient Therapeutics has inked a new deal with leading research organisation Peter MacCallum Cancer Centre...
The market for revolutionary CAR-T cancer treatments is expected to grow to USD 14 billion...
When JVC launched VHS videos in 1971, it started a consumer revolution that permanently altered...
The burgeoning CAR T therapy industry has passed another significant milestone after the US Food...
Australian listed biotech company Prescient Therapeutics (ASX: PTX) is forging a path for other prospective...
Several major pharmaceutical companies have cautioned they’re unable to widely use revolutionary CAR-T cancer treatments,...
In the battle against blood cancer, chimeric antigen receptor T cell (CAR-T) therapy is proving...
Every year 45,000 of the most respected professionals in oncology gather at the American Society...
Last month, the best and brightest minds in oncology gathered (virtually) for the American Society...
ASX listed biotech company Prescient Therapeutics (ASX: PTX) has this week unveiled two significant licence...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.